Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis

被引:138
|
作者
Gao, Guoxuan [1 ,2 ]
Wang, Zihan [1 ,2 ]
Qu, Xiang [1 ,2 ]
Zhang, Zhongtao [1 ,2 ]
机构
[1] Capital Med Univ, Dept Gen Surg, Beijing Friendship Hosp, Beijing Key Lab Canc Invas & Metastasis Res, 95 Yong An Rd, Beijing 100050, Peoples R China
[2] Natl Clin Res Ctr Digest Dis, 95 Yong An Rd, Beijing 100050, Peoples R China
关键词
Triple-negative breast cancer; Tumor-infiltrating lymphocytes; Prognosis; Meta-analysis; PATHOLOGICAL COMPLETE RESPONSE; DISEASE-FREE SURVIVAL; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; RESIDUAL DISEASE; PD-L1; EXPRESSION; PREDICTIVE-VALUE; CELLS; SUBTYPES; BENEFIT;
D O I
10.1186/s12885-020-6668-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The objective of this systematic review and meta-analysis was to determine the prognostic value of total tumor-infiltrating lymphocytes (TILs) and subtypes of TILs (CD4(+), CD8(+), and FOXP3(+)) in triple-negative breast cancer (TNBC). Methods A systematic search of the MEDLINE, EMBASE, and Web of Science databases was conducted to identified eligible articles published before August 2019. Study screening, data extraction, and risk of bias assessment were performed by two independent reviewers. Risk of bias on the study level was assessed using the ROBINS I tool and Quality in Prognosis Studies (QUIPS) tool. We performed a meta-analysis to obtain a pooled estimate of the prognostic role of TILs using Review Manager 5.3. Results In total, 37 studies were included in the final analysis. Compared to TNBC patients with low TIL levels, TNBC patients with high TIL levels showed a higher rate of pathological complete response (pCR) to treatment (odds ratio [OR] 2.14, 95% confidence interval [CI] 1.43-3.19). With each 10% increase in percentage of TILs, patients with TNBC had an increased pCR (OR 1.09, 95% CI 1.02-1.16). Compared to TNBC patients with low TIL levels, patients with high TIL levels had better overall survival (OS; hazard ratio [HR] 0.58, 95% CI 0.48-0.71) and disease-free survival (DFS; HR 0.66, 95% CI 0.57-0.76). Additionally, with a continuous increase in TIL levels, patients with TNBC had improved OS (HR 0.90, 95% CI 0.87-0.93) and DFS (HR 0.92, 95% CI 0.90-0.95). A high CD4(+) TIL level was associated with better OS (HR 0.49, 95% CI 0.32-0.76) and DFS (HR 0.54, 95% CI 0.36-0.80). A high CD8(+) TIL level was associated better DFS only (HR 0.55, 95% CI 0.38-0.81), as no statistical association was found with OS (HR 0.70, 95% CI 0.46-1.06). A high FOXP3(+) TIL level also was associated with only DFS (HR 0.50, 95% CI 0.33-0.75) and not OS (HR 1.28, 95% CI 0.24-6.88). Conclusions TNBC with a high level of TILs showed better short-term and long-term prognoses. High levels of specific phenotypes of TILs (CD4(+), CD8(+), and FOXP3(+)) were predictive of a positive long-term prognosis for TNBC.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Prognostic value of tumor-infiltrating lymphocytes in DCIS: a meta-analysis
    Wu, Shuang-Ling
    Yu, Xinmiao
    Mao, Xiaoyun
    Jin, Feng
    [J]. BMC CANCER, 2022, 22 (01)
  • [32] Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization
    Sofia Gomez-Macias, Gabriela
    Molinar-Flores, Guillermo
    Lopez-Garcia, Carlos A.
    Santuario-Facio, Sandra
    Decanini-Arcaute, Horacio
    Valero-Elizondo, Javier
    Trevino-Alvarado, Victor
    Ortiz-Lopez, Rocio
    Dono, Antonio
    Esteban-Zubero, Eduardo
    Alatorre-Jimenez, Moises A.
    Villarreal Garza, Cynthia
    Pena-Curiel, Omar
    Cardona-Huerta, Servando
    [J]. ONCOLOGY LETTERS, 2020, 20 (05)
  • [33] Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Floris, Giuseppe
    Richard, Francois
    Hamy, Anne-Sophie
    Jongen, Lynn
    Wildiers, Hans
    Ardui, Jan
    Punie, Kevin
    Smeets, Ann
    Berteloot, Patrick
    Vergote, Ignace
    De Croze, Diane
    Meseure, Didier
    Salomon, Anne
    Lae, Marick
    Reyal, Fabien
    Biganzoli, Elia
    Neven, Patrick
    Desmedt, Christine
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (02) : 146 - 153
  • [36] Prognostic value of routinely determined tumor infiltrating lymphocytes in triple-negative breast cancer.
    Golicnik, Jana Pahole
    Gazic, Barbara
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Prognostic Value of Differentially Expressed LncRNAs in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
    Tuluhong, Dilihumaer
    Dunzhu, Wangmu
    Wang, Jingjie
    Chen, Tao
    Li, Hanjun
    Li, Qiurong
    Wang, Shaohua
    [J]. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2020, 30 (05): : 447 - 456
  • [38] Effect of Lipid Levels on Tumor-Infiltrating Lymphocytes and Prognosis in Patients with Triple-Negative Breast Cancer
    AiErken, NiJiati
    Shao, Nan
    Liu, Yuhong
    Shi, Huijuan
    Shi, Yawei
    Yuan, Zhongyu
    Lin, Ying
    [J]. BREAST CARE, 2023, 18 (05) : 390 - 398
  • [39] Correlation Between MRI and the Level of Tumor-Infiltrating Lymphocytes in Patients With Triple-Negative Breast Cancer
    Ku, You Jin
    Kim, Hak Hee
    Cha, Joo Hee
    Shin, Hee Jung
    Baek, Soo Heui
    Lee, Hee Jin
    Gong, Gyungyub
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2016, 207 (05) : 1146 - 1151
  • [40] Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
    Geurts, Veerle C. M.
    Balduzzi, Sara
    Steenbruggen, Tessa G.
    Linn, Sabine C.
    Siesling, Sabine
    Badve, Sunil S.
    DeMichele, Angela
    Ignatiadis, Michail
    Leon-Ferre, Roberto A.
    Goetz, Matthew P.
    Wolff, Antonio C.
    Klar, Natalie
    Michiels, Stefan
    Loi, Sherene
    Adams, Sylvia
    Horlings, Hugo M.
    Sonke, Gabe S.
    Salgado, Roberto
    Kok, Marleen
    [J]. JAMA ONCOLOGY, 2024,